OncoMatch/Clinical Trials/NCT06069570
Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases
Is NCT06069570 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies KB-GDT-01 for carcinoma, non-small-cell lung cancer.
Treatment: KB-GDT-01 — This is a clinical trial studying intravenous infusions of allogeneic gamma delta T cells after receiving low dose radiotherapy in participants with locally advanced or metastatic non-small cell lung cancer or solid tumors with bone metastases to evaluate the safety and efficacy of combining immunotherapy with radiation therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Biomarker criteria
Allowed: ALK actionable molecular alteration
Allowed: BRAF actionable molecular alteration
Allowed: EGFR actionable molecular alteration
Allowed: KRAS actionable molecular alteration
Allowed: MET actionable molecular alteration
Allowed: RET actionable molecular alteration
Allowed: ROS1 actionable molecular alteration
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy — NSCLC
Progressed on SOC therapy including platinum-based chemotherapy
Must have received: checkpoint inhibitor — NSCLC
Progressed on SOC therapy including...immune checkpoint inhibitors (NSCLC)
Must have received: targeted therapy — tumors with actionable molecular alterations
tumors with known actionable molecular alterations...must have progressed on appropriate target-directed molecular therapy
Must have received: zoledronic acid (zoledronic acid) — solid tumors with bone metastases (Part 2 Cohort B)
receiving zoledronic acid for solid tumors with bone metastases
Cannot have received: chemotherapy
Chemotherapy...within the 30 days prior to study Day 1
Cannot have received: checkpoint inhibitor
check-point inhibitor therapy within the 30 days prior to study Day 1
Cannot have received: investigational therapy
investigational...therapy within the 30 days prior to study Day 1
Cannot have received: radiation therapy
Prior radiation therapy to a selected LDRT treatment site </= 30 days prior to Day 1
Lab requirements
Blood counts
adequate hematopoietic function
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
cardiac ejection fraction ≤ 50%, history of arrhythmia including atrial fibrillation, unstable angina, decompensated congestive heart failure, myocardial infarction, or marked baseline prolonged QT/QTc intervals [excluded]
Adequate hematopoietic, hepatic and renal function. Uncontrolled hypertension, history of arrhythmia including atrial fibrillation, unstable angina, decompensated congestive heart failure, cardiac ejection fraction ≤ 50%, myocardial infarction, or marked baseline prolonged QT/QTc intervals [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- The University of Arizona Cancer Center · Tucson, Arizona
- Beverly Hills Cancer Center · Beverly Hills, California
- UPMC Hillman Cancer Center · Pittsburgh, Pennsylvania
- Texas Oncology - Tyler · Tyler, Texas
- Virginia Oncology Associates · Norfolk, Virginia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify